{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-196284","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2023-07-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.763055+00:00","generated_at":"2026-06-13T00:36:10.408757+00:00","sec_items":["2.05","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Homology Medicines cuts ~80 employees, initiates strategic review","bullets":["Reduction in force of ~80 employees, including CMO Julie Jordan; CCO Michael Blum retained as consultant.","Estimated restructuring charges of ~$6.8M (severance, benefits) expected in Q3 2023.","Board begins process to explore strategic options including acquisition, merger, or sale of assets.","Actions aimed at reducing operating expenses and maximizing shareholder value."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-196284","json":"https://secwatch.observer/filing/0001193125-23-196284.json","markdown":"https://secwatch.observer/filing/0001193125-23-196284.md","text":"https://secwatch.observer/filing/0001193125-23-196284.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000119312523196284/0001193125-23-196284-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000119312523196284/d510598d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T00:36:10.408757+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3d527cb018742be4baca105f07541714fe6c6f7c","claim":"Q32 Bio Inc. announced a restructuring with charges of approximately $6.8 million (approximately 80 employees).","evidence_excerpt":"On July 25, 2023, the Board of Directors (the “ Board ”) of Homology Medicines, Inc. (the “ Company ”) approved a reduction in the Company’s current workforce by approximately 80 employees. The decision was based on cost-reduction initiatives intended to reduce the Company’s ongoing operating expenses and maximize shareholder value as the Company plans to pursue strategic options. The reduction in force included Julie Jordan, M.D., the Company’s Chief Medical Officer and Michael Blum, the Company’s Chief Commercial Officer. The Company intends to retain Mr. Blum as a consultant. The Company currently estimates that it will incur approximately $6.8 million in charges in connection with the reduction in force, primarily consisting of severance payments, employee benefits and related costs, including tax costs and excluding noncash expenses associated with share-based awards.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661998/000119312523196284/0001193125-23-196284-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $6.8 million"},{"label":"Headcount","value":"approximately 80 employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}